Merck & Co Stock Rating Reaffirmed by TheStreet (MRK)
Merck & Co (NYSE:MRK)‘s stock had its “buy” rating reiterated by equities research analysts at TheStreet in a research note issued to investors on Monday, AnalystRatings.NET reports.
The analysts wrote, “Merck (MRK) has been reiterated by TheStreet Ratings as a buy with a ratings score of B+. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
Shares of Merck & Co (NYSE:MRK) opened at 52.96 on Monday. Merck & Co has a 1-year low of $40.83 and a 1-year high of $54.10. The stock’s 50-day moving average is $50.66 and its 200-day moving average is $48.45. The company has a market cap of $154.7 billion and a price-to-earnings ratio of 35.60.
A number of other firms have also recently commented on MRK. Analysts at Morgan Stanley upgraded shares of Merck & Co from an “equal weight” rating to an “overweight” rating in a research note to investors on Monday, January 27th. They now have a $60.00 price target on the stock. Separately, analysts at MKM Partners raised their price target on shares of Merck & Co from $59.00 to $64.00 in a research note to investors on Tuesday, January 14th. They now have a “buy” rating on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Merck & Co from $51.00 to $54.00 in a research note to investors on Thursday, January 9th. They now have a “hold” rating on the stock. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $53.81.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.